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Cytolethal distending toxins (CDT) constitute an emerging heterogeneous family of bacterial toxins whose
common biological property is to inhibit the proliferation of cells in culture by blocking their cycle at G2/M
phase. In this study, we investigated the molecular mechanisms underlying the block caused by CDT from
Escherichia coli on synchronized HeLa cell cultures. To this end, we studied specifically the behavior of the two
subunits of the complex that determines entry into mitosis, i.e., cyclin B1, the regulatory unit, and cdc2 protein
kinase, the catalytic unit. We thus demonstrate that CDT causes cell accumulation in G2 and not in M, that
it does not slow the progression of cells through S phase, and that it does not affect the normal increase of
cyclin B1 from late S to G2. On the other hand, we show that CDT inhibits the kinase activity of cdc2 by
preventing its dephosphorylation, an event which, in normal cells, triggers mitosis. This inhibitory activity was
demonstrated for the three partially related CDTs so far described for E. coli. Moreover, we provide evidence
that cells exposed to CDT during G2 and M phases are blocked only at the subsequent G2 phase. This
observation means that the toxin triggers a mechanism of cell arrest that is initiated in S phase and therefore
possibly related to the DNA damage checkpoint system.
Cytolethal distending toxins (CDT) constitute an emerging
toxin family whose members have been found in several unre-
lated bacterial species of medical interest, including Esche-
richia coli (12, 23, 24, 30), Shigella dysenteriae (19), Campy-
lobacter sp. (18, 25), and Haemophilus ducreyi (3). In all cases,
the genetic structure encoding CDT activity included three
adjacent or slightly overlapping chromosomal genes (called
cdtA, cdtB, and cdtC) encoding proteins with similar molecular
masses (27, 29, and 20 kDa, respectively). In E. coli, CDT
genes were characterized in two enteropathogenic strains (24,
30), where they are chromosomally encoded, and, in a necro-
toxigenic strain also producing cytotoxic necrotizing factor 2,
where they are plasmid encoded (23). However, the percent-
age of identity of the predicted proteins is highly variable and
shows the heterogeneity of CDT, even within E. coli species.
CDT was originally defined by its ability to induce giant
elongated cells in CHO tissue cultures upon prolonged incu-
bation (12). The biological activity exerted by CDT on cell
cultures has been more precisely defined on the HeLa epithe-
lial cell line (23). The three types of CDT from E. coli de-
scribed above were all shown to inhibit cell division, causing an
irreversible block at the G2/M stage of the cell cycle. This
mitotic block leads to cell death only 3 to 5 days after exposure
to the toxin, a period of time during which cells continue to
synthesize proteins and to grow, becoming up to 10-fold larger
than control cells (23). Inhibition of eukaryotic cell division
through specific blocking in G2/M phase of the cell cycle con-
stitutes an original mode of action for a bacterial toxin. Inter-
estingly, this activity bears some resemblance with that exerted
by such unrelated agents as the Vpr protein of human immu-
nodeficiency virus type 1 (28, 29) and several DNA-damaging
agents, which also cause a block in G2/M phase of the HeLa
cell cycle (15).
Cyclin-dependent kinases in association with their cyclin reg-
ulatory units regulate progression through the cell cycle. A
complex between the cdc2 (cdk1) protein kinase and cyclin B
has been shown to control entry into mitosis in every eukary-
otic species (5, 17). The cellular concentration and distribution
of cyclin B1 and the state of activation of cdc2 are known to be
critical determinants of the transition from G2 to mitosis (11,
17). In normal cells, cyclin B1 accumulates in the cytoplasm of
interphase cells and enters the nucleus only at the beginning of
mitosis, before nuclear lamina breakdown (27). cdc2 is ex-
pressed at a constant level over the different phases of the cell
cycle, but its tyrosine phosphorylation status increases during
interphase to reach a maximum level in late G2. Mitosis is then
initiated by cdc25-phosphatase-dependent dephosphorylation
of cdc2, an event which fully activates cdc2 kinase (4, 17). In
the present study, we sought first to define more precisely the
stage at which the HeLa cell cycle was blocked by CDT and
second to determine the molecular mechanism underlying this
block. To this end, we have monitored on synchronized HeLa
cells the early events that occur between cell exposure to the
toxin and imposition of the G2/M block. We have shown that
CDT blocks the cell cycle in G2, and not in M, and that it
prevents the dephosphorylation-dependent activation of the
cdc2-cyclin B complex. Moreover, we provide evidence that the
G2 block induced by CDT is triggered through pathways that
are similar to those utilized by DNA-damaging agents.
MATERIALS AND METHODS
CDT preparation and determination of cytotoxic endpoint. CDT-I was pro-
duced from E. coli DH5 hosting recombinant plasmid pDS7.96, which contains
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the three open reading frames (cdtA, cdtB, and cdtC) necessary to encode CDT
activity (30). This strain was kindly provided by James Kaper, Center for Vaccine
Development, University of Maryland. The toxic preparation consisted in the
sterile supernatant of a 24-h Trypticase soy broth aerated culture. The control
preparation consisted of the supernatant of E. coli DH5 hosting the same
cloning plasmid (pUC19) without insert. CDT-II and CDT-III preparations were
produced as sterile sonicated lysates from E. coli DH5 containing recombinant
plasmid pCP2123 (24) (kindly provided by Carol Pickett, Chandler Medical
Center, University of Kentucky) and recombinant plasmid pEOFH10 (23), from
our laboratory, respectively. The toxic and control preparations were aliquoted
and kept at 20°C.
For each preparation, the 95% cytotoxic dose (CD95) was defined as the
highest dilution which, following a 1-h application on HeLa cell cultures, gave at
least 95% elongated cells after 72 h of incubation (23). Unless otherwise spec-
ified, 2 CD95 was used in all experiments described below. The control prepa-
ration (from DH5 hosting pUC19) did not display any significant decrease in
cell growth or any morphological alteration compared to untreated cells. In the
text, “control cells” refers to cells exposed to the control preparation.
Cell synchronization and flow cytometry analysis of DNA and cyclin B1 con-
tents. HeLa cells (ATCC CCL2) were grown at 37°C in Eagle minimal essential
medium with Earle’s salt, L-glutamine (200 mM), and 10% fetal calf serum in a
5% CO2 atmosphere. Synchronization at the G1/S border was performed on
nonconfluent cell cultures (about 106 for a 10-cm-diameter culture dish) by the
double thymidine block (DTB) method (31), and synchronization in mitosis
(prometaphase) was performed by culture in the presence of nocodazole (100
nM) for 16 h as described previously (31).
For the analysis of DNA content by flow cytometry, cells were trypsinized,
washed in phosphate-buffered saline (PBS) and then fixed in 1% formaldehyde
in PBS (pH 7.4) for 15 min on ice. Then, after three washes in PBS, they were
suspended in 70% ice-cold ethanol and immediately kept at 20°C for at least
2 h. After fixation, cells (about 106) were rehydrated in PBS for 30 min at room
temperature, permeabilized by 0.1% Triton X-100 in PBS (pH 7.4), and incu-
bated at 4°C for 30 min in the dark in 1 ml of PBS containing propidium iodide
(PI; 10 g/ml; Sigma) and RNase (1 mg/ml; Sigma).
For the combined analysis of both cyclin B1 and DNA in flow cytometry (8),
cells (about 106) were trypsinized, fixed, and kept in 70% ethanol as described
above. After rehydration in PBS, they were permeabilized with 0.25% Triton
X-100 for 5 min on ice and incubated overnight at 4°C in the presence of the
mouse monoclonal antibody GNS-1 (Pharmingen) diluted 1:100 in PBS contain-
ing 1% bovine serum albumin (BSA). Cells were then washed and incubated for
1 h with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immu-
noglobulin G (IgG) antibody (Sigma) diluted 1:40 in PBS containing 1% BSA.
The cells were washed again, resuspended in 1 ml of PBS containing PI (10
g/ml; Sigma) and RNase (1 mg/ml; Sigma), and incubated for 30 min at room
temperature in the dark.
Flow cytometry analysis was performed on a FACScalibur flow cytometer
(Becton Dickinson), using the red (PI) emission (630 nm) for DNA quantifica-
tion and green (FITC) emission (530 nm) for cyclin B1 quantification. The data
from 104 cells were collected and analyzed by using CellQuest software (Becton
Dickinson).
Fluorescence microscopy. HeLa cells were cultivated in eight-well Lab-Tek
tissue culture chamber slides (Nunc). At specified times, they were washed with
PBS and fixed with absolute methanol at 20°C for 6 min. After drying, cells
were rehydrated in PBS containing 1% BSA and incubated overnight at 4°C in
the presence of a 1:100 dilution in PBS (containing 1% BSA) of one the follow-
ing monoclonal antibodies: mouse BF683 (Pharmingen) for cyclin A, mouse
GNS-1 (Pharmingen) for cyclin B1, or rat YL1/2 (Sera-lab) for -tubulin. After
three washes in PBS, cells were incubated for 1 h in the presence of FITC-
conjugated goat anti-mouse IgG antibody (Sigma) or rabbit anti-rat IgG anti-
body (Vector), diluted 1:40 in PBS containing 1% BSA. After a further step of
DNA staining with diaminophenylindole (DAPI; 0.1 g/ml) in the case of mi-
crotubule staining and three more washes in PBS, slides were mounted in
Vectashield mounting medium (Vector) and examined by fluorescence micros-
copy (Leica DMRB fluorescence microscope), using a 40 fluorescence immer-
sion objective lens.
cdc2 purification from cell lysates. After cultivation in the conditions specified
in Results, HeLa cells were trypsinized and then washed in Earle balanced salt
solution (Gibco). The cell pellet was lysed in an Eppendorf tube for 15 min on
ice in a 50 mM Tris-HCl buffer (pH 7.4) containing Triton X-100 (0.1%), NaCl
(150 mM), MgCl2 (10 mM), EDTA (5 mM), NaF (50 mM), dithiothreitol (1
mM), glycerophosphate (50 mM), orthovanadate (0.1 mM), and protease inhib-
itor cocktail (complete; Boehringer, Mannheim, Germany). The lysate was then
centrifuged at 4°C (15,000 rpm, 10 min) to eliminate the insoluble fraction, and
the protein content of the supernatant was determined by the Bio-Rad protein
assay.
cdc2 was then purified from lysates by using a commercial product consisting
of recombinant yeast p13suc1 covalently bound by CNBr to agarose (Upstate
Biotechnology). Lysates (2 mg of total protein for Western blot analysis and 200
g for kinase activity) were reconstituted in lysis buffer in a final volume of 1 ml,
to which 25 l of p13-agarose beads was added. After 2 h of incubation with
agitation at 4°C, beads were pelleted by centrifugation and washed twice in the
lysis buffer before kinase assay or Western blot analysis.
Histone H1 kinase assay. The ability of purified cdc2 from cell lysates to
phosphorylate histone H1 was assessed as previously described (7). Pellets of
purified cdc2 complexed to p13-agarose conjugate, prepared as described above,
were suspended in 40 l of a reaction mix containing Tris-HCl (100 mM; pH 7.4),
MgCl2 (10 mM), dithiothreitol (1 mM), ATP (100 M; Sigma), calf thymus
histone H1 (400 g/ml; Boehringer), and [-32P]ATP (125 Ci/ml; Amersham)
and incubated for 30 min in a 30°C water bath. After incubation, beads were
eliminated by centrifugation and 8-l aliquots of the supernatant were pipetted
onto 1- by 1-cm pieces of P81 ion-exchange paper (Whatman), which specifically
retains histone H1. Four aliquots, including a negative control for the calculation
of background radioactivity, were tested for each experimental point. Papers
were immersed in tap water containing 150 mM H3PO4, with five changes of
water. After a final rinsing in ethanol and drying, pieces of paper were trans-
ferred to scintillation vials to which scintillation fluid (Aquasafe 500; Zinsser
Analytic) was added. Radioactivity was determined by liquid scintillation count-
ing. The kinase activity of each lysate was defined as the mean counts per minute
minus mean background value.
Western blot analysis of cdc2. cdc2 bound to p13-agarose conjugates, prepared
as described above, was extracted with 40 l of sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE) sample buffer, and run in SDS-
PAGE (12% gel), using color wide-range molecular weight markers (Sigma).
Proteins were blotted onto Immobilon-P membrane (Millipore) filters, using 10
mM cyclohexylamino-1-propanesulfonic acid buffer (Research Organics) con-
taining 10% methanol. The membrane was cut between markers of 29 and 45
kDa and blocked by Superblock blocking buffer (Pierce) containing orthovana-
date (0.5 mM). In the first step, the membrane was then incubated overnight at
4°C with antiphosphotyrosine monoclonal antibody clone 4G10 (Upstate Bio-
technology) diluted 1:1,000 in PBS containing 0.1% Tween 20, 5% goat serum,
and 0.5 mM orthovanadate, followed, after three washes in PBS, by secondary
goat anti-mouse IgG (Fab specific)-peroxidase conjugate diluted 1:5,000 as de-
scribed above (Sigma). The blot was developed by using the ECL chemilumi-
nescence detection system (Amersham). In the second step, the membrane was
stripped in 70 mM Tris-HCl (pH 6.8) containing 2% SDS and 100 mM 2-
mercaptoethanol, blocked as described above, and reprobed overnight with rab-
bit anti-cdc2 kinase peptide antibody against the carboxyl terminus (Gibco)
diluted 1:500 as described above, followed by secondary goat anti-rabbit IgG-
peroxidase conjugate (Biosys) diluted 1:800. The blot was developed as described
above.
RESULTS
The G2/M block caused by CDT is not dependent on cell
cycle status at time of exposure. We first checked if the sus-
ceptibility of HeLa cells to CDT was dependent on position in
the cell cycle. Cells synchronized at G1/S by the DTB method,
in S phase (4 h after release from DTB) and in G2 phase (8 h
after release from DTB), and in M phase by nocodazole were
exposed for 1 h to the CDT-I or to the control preparation.
Cell cycle distribution was then analyzed by flow cytometry
analysis of DNA content 24 h after the exposure period (Fig.
1). When exposed to CDT, the large majority of cells accumu-
lated in G2/M, irrespective of their position in the cell cycle at
the time of exposure. In contrast, control cells analyzed at the
same time displayed a clearly different pattern, returning to an
almost asynchronized normal distribution 24 h after G2 and M
exposure.
In the same way, no significant difference was observed in
the overall sensitivity of cells to CDT according to their posi-
tion in the cell cycle, as shown by a dose-response study in
microtiter plates. The estimated CD95 was not significantly
different from that observed with unsynchronized cells (i.e., it
corresponded to a 1/1,280 dilution of the culture supernatant).
Cells exposed to CDT during G2 and M phases are arrested
at the subsequent G2/M phase. The data displayed in Fig. 1
indicate that cells exposed to CDT at the G1/S border or in S
phase were arrested in the same cycle, since they could not
have reached the next G2/M phase within a 24 h period of time.
This is in agreement with the known durations of the phases of
HeLa cell cycle, which are about 7 h for G1, 8 h for S, 4 h for
G2, and 1 h for M (31). However, it was not possible from the
data displayed in Fig. 1 to determine whether cells exposed in
G2 and M phases were arrested during the same cycle or
during the subsequent one, since they could well have reached
a new G2/M phase after a 24-h period of time. To elucidate this
matter, we exposed cells synchronized in G2 to the toxin for 1 h
and studied their DNA distribution after shorter times of in-
cubation after exposure (15, 18, and 24 h). As shown in Fig. 2,
15 h after exposure in G2, a large majority of cells had initiated
a new cycle, and they were blocked in G2/M only after 24 h of
incubation. These results show that most of the cells exposed in
G2 were not blocked in the same cycle but that they had to go
through a S phase to be arrested at the subsequent G2/M
transition. The same observation was made with cells synchro-
nized in mitosis by nocodazole (not shown). In addition, it may
be relevant that although the large majority of cells exposed in
G2 were arrested in G2/M, a minority (approximately 15%)
were arrested in G1 (Fig. 1 and 2).
CDT does not affect progression through S phase. The fore-
going results did not indicate whether progression through S
phase was slowed by the toxin, as is the case, for example, with
some DNA-damaging agents also causing a G2/M block (15).
To elucidate this point, we exposed the synchronized cells to
the toxin or the control preparation for 1 h at the G1/S border
and analyzed their DNA content by flow cytometry 8 h later.
As shown in Fig. 3, the progression of CDT-exposed cells
through S phase did not differ significantly from that of control
cells, since 50 and 59% of cells, respectively, were estimated to
be positioned in the G2 peak at that time.
Cyclin B1 increase is not affected by CDT during G2 pro-
gression, but cells are blocked before prophase initiation. As
shown by fluorescence microscopy after staining of cellular
DNA with DAPI, no figure of mitosis, including early prophase
with characteristic chromatin condensation and reorganization
of microtubules into mitotic spindle, was observable in cells
arrested by CDT 24 h after exposure (Fig. 4). This observation
suggested that cells accumulated before initiation of prophase.
To corroborate this hypothesis, we monitored the expression
of cyclin A and cyclin B1 during progression of cells toward the
block. As shown previously, these two cyclins are considered
relevant indicators of progression through G2 and M phases
since their level increases progressively from late S to M phase.
In normal cells, cyclin A is degraded during mitosis just prior
to metaphase, whereas degradation of cyclin B1 occurs later, at
the transition between metaphase and anaphase (8, 27). The
concentration and distribution of cyclins A and B1 in unsyn-
chronized control cells and in cells blocked by CDT (24 h after
exposure) were first examined by immunofluorescence micros-
copy (Fig. 5). In asynchronized control cells, the intensity and
cellular distribution of cyclins A and B1 were dependent on
position in the cell cycle. Cyclin A was located exclusively in
the nucleus, and its intensity increased up to prophase (Fig.
5A). The highest concentration of cyclin B1 was observed in
the nucleus during prophase and metaphase. In interphase
cells, cyclin B1 remained located in the perinuclear area and
was readily perceptible only in late G2 in our experimental
conditions (Fig. 5C). In cells blocked by CDT, 24 h after
exposure the intensity and distribution of both cyclin A and
FIG. 1. Induction of G2/M block by CDT in synchronized HeLa cells exposed in G1/S, S, and G2. HeLa cells were synchronized at the G1/S border by the DTB
method. They were exposed for 1 h to CDT-I or the control preparation at time of release (G1/S), 4 h later (S), or 8 h later (G2). Cell distribution according to DNA
content was analyzed just before exposure or 24 h later by flow cytometry after staining of DNA with PI. About 10,000 cells were analyzed per sample. In each case,
the G1 peak was arbitrarily centered at channel 200. In all cases, cells exposed to the toxin were blocked in G2/M 24 h after exposure.
cyclin B1 were highly homogeneous among cells. Cyclin A
clearly accumulated in the nucleus, without reaching the level
of intensity observed with control cells in prophase (Fig. 5B).
Cyclin B1 also accumulated in the perinuclear area up to the
level of late G2 control cells, without translocating in the nu-
cleus (Fig. 5D). These observations confirm that at least in the
early phases of the block, cells did not proceed past the G2
stage.
Cyclin B1 expression was then monitored quantitatively by
flow cytometry in synchronized cells after release from G1/S
block followed by 1 h of exposure to the toxin or the control
preparation (Fig. 6). In control cells, the pattern of cyclin B1
expression was in accordance with previous observations (8),
i.e., a steady increase from end of S phase up to 11 h, a time
that corresponds approximately to entry in mitosis. In CDT-
treated cells, which were blocked in G2, the average level of
cyclin B1 was not significantly different from that of control
cells up to 11 h. However, at 11 h, the increase in cyclin B1 was
not stopped in CDT-treated cells, in contrast to control cells
(P  0.05). The continued increase of cyclin B1 in CDT-
treated cells in the long term was confirmed in assays using
unsynchronized cells (Fig. 7). We observed that the average
content of cyclin B1 in cells exposed to CDT increased by a
factor 2.1 (163/77) from 4 to 16 h after exposure and a factor
3.6 (280/77) from 4 to 48 h after exposure. The quantitative
determination of cyclin B1 by flow cytometry analysis con-
firmed that CDT-treated cells were arrested in late G2 (and not
in M) and showed that the toxin did not interfere with the
regular increase of cyclin B1 during cycle progression to G2 or
with its continued synthesis after establishment of the G2 block
itself. This result further suggested that cyclin B1, the regula-
tory subunit of the mitosis promoting complex, was not itself
directly affected by the toxin and thus prompted us to investi-
gate a possible modification of cdc2, the catalytic subunit of
this complex.
The cdc2 protein kinase is inactivated by CDT. We com-
pared the kinase activity and state of phosphorylation of cdc2
in control and CDT-exposed asynchronous cells 24 h after
exposure. Cells arrested in prometaphase by nocodazole were
used as a positive control. To extend the validity of our results,
we performed this experiment on the three partially related
types of E. coli CDT so far described (23, 24, 30). As shown in
Fig. 8, cells blocked in G2 by all three CDTs displayed a low
level of kinase activity, not significantly different from that of
control cells in interphase and roughly 8 to 10% of the activity
of nocodazole-treated cells. The phosphorylation status of
cdc2 in the same samples was studied by Western blot analysis
after affinity purification using p13suc-1-agarose conjugate (Fig.
8). Using antiphosphotyrosine antibodies and, after stripping
of the blotting membrane, anti-cdc2 antibodies, we demon-
strated the existence of the three isoforms of cdc2, with a clear
concentration of the slow-migrating, highly phosphorylated
form of cdc2 in cells exposed to the three CDTs and blocked in
G2. In the normal, asynchronous population of cells exposed to
the control preparation, the lack of kinase activity was associ-
ated, as expected, with an overall low level of tyrosine phos-
phorylation and with a higher concentration of the lower fast-
migrating band. In nocodazole-treated cells arrested in
prometaphase, the lower isoform was dominant, and, interest-
ingly, the intermediate band appeared to be also slightly ty-
rosine phosphorylated. We presume that this reflected the
presence of a dephosphorylation intermediate that is phos-
phorylated on both tyrosine 15 and threonine 161 but not on
threonine 14 (2). Altogether, these observations led us to the
conclusion that CDT blocks the cell cycle progression at the
FIG. 2. Demonstration that most of the cells exposed to CDT during G2
phase of the cell cycle were arrested only at the subsequent G2 phase. HeLa cells
were synchronized in G2 by the DTB method followed by 8 h of incubation. They
were then exposed to CDT-I or the control preparation for 1 h. Cell cycle
progression was assessed by flow cytometry quantification of PI-stained DNA at
15, 18, and 24 h after exposure to the toxin. About 10,000 cells (4,000 at 24 h)
were analyzed per sample. In each case, the G1 peak was arbitrarily centered at
channel 200.
FIG. 3. Progression of synchronized HeLa cells from G1/S through S phase
following exposure to CDT. HeLa cells were synchronized at the G1/S border by
the DTB method. At the time of release from G1/S, they were exposed for 1 h to
CDT-I or to the control preparation. Eight hours later, a time which corresponds
roughly to the end of S phase, DNA content was analyzed by flow cytometry after
PI staining. About 10,000 cells were analyzed per sample. In each case, the G1
peak was arbitrarily centered at channel 200. S phase was not significantly slowed
by CDT compared to the control preparation.
G2/M transition by preventing cdc2 protein kinase dephos-
phorylation and subsequent activation.
DISCUSSION
In this study, we investigated the early events that follow
exposure of HeLa cells to E. coli CDT, in an attempt to clarify
the mechanisms that lead to the G2/M block reported previ-
ously (23). We have demonstrated (i) that cells accumulate in
late G2 (and not M), (ii) that the G2-phase block is associated
with stabilization of the hyperphosphorylated form of the cdc2
protein kinase, and (iii) that the toxin interferes with a cellular
mechanism that is triggered in S phase.
Our demonstration that cells accumulated in G2, and not in
FIG. 4. Fluorescence microscopy of cells exposed for 1 h to CDT-I (B and D [same field]) or the control preparation (A and C [same field]) 24 h after exposure.
(A and C) DAPI staining; (C and D) microtubule staining. Note the absence of mitotic figures and the increased nuclear size in CDT-treated cells compared to control
cells, where several figures of mitosis are visible (arrowheads).
FIG. 5. Fluorescence microscopy of cyclin A (A and B) and cyclin B1 (C and D) distribution in asynchronous control cells (A and C) and CDT-I-treated cells (B
and D) 24 h after exposure. Cyclins were stained by indirect immunofluorescence using FITC-conjugated antibodies as the secondary reagent. Note in particular that
in CDT-treated cells, the distribution and intensity of both cyclin A (nuclear) and cyclin B1 (perinuclear) are highly homogeneous, indicating a block in late G2. By
contrast, cyclin contents of control cells are highly heterogeneous (mitotic cells are indicated by arrowheads).
M, is based primarily on the fact that blocked cells did not
display in fluorescence microscopy any mitotic figures 24 h
after exposure, using DNA- and microtubule-specific staining.
More specifically, we observed no early condensation of chro-
matin or any significant reorganization of microtubules into a
mitotic spindle in these cells (Fig. 4). This observation was
confirmed by fluorescence microscopy of cyclin A and cyclin
B1, whose localization and concentration indicate that cells
were arrested in late G2. We reported previously that this block
was irreversible and that cell death of blocked cells started
from about 72 h after exposure (23). The description of the
delayed events that precede cell death and analysis of its bio-
logical determinism will be the subject of a future study.
To approach the determinism of the G2 block caused by
CDT, we monitored the behavior of the cdc2 protein kinase
and of cyclin B1, its regulatory unit (17). We first demonstrated
by flow cytometry analysis that cyclin B1 expression was not
significantly affected in synchronous cells exposed in G1/S com-
pared to synchronous control cells (Fig. 6). During S and G2
progression, cyclin B1 accumulated in exposed cells at approx-
imately the same rate as in control cells, in accordance with
previously described pattern (8). However, the overall level of
cyclin B1 continued to increase significantly at least up to 48 h
after exposure (Fig. 7) while, as expected (8), it dropped in
control cells at entry into mitosis. These data demonstrate that
the block cannot be accounted for by a lack of cyclin B1
expression.
The role of cdc2 was assessed by using two complementary
approaches: quantification of its kinase activity and molecular
analysis of its phosphorylation status in SDS-PAGE immuno-
blotting. Our results show that 24 h after exposure, blocked
cells had a low level of cdc2 kinase activity, which was associ-
ated with the stabilization of the hyperphosphorylated slow-
migrating form of the molecule (Fig. 8). Since dephosphory-
lation of cdc2 on Tyr-15 and Thr-14 residues is a prerequisite
for its activation and for entry into mitosis, and since cyclin B1,
its regulatory subunit, was apparently not affected in CDT-
exposed cells, we can reasonably infer from our results that the
absence of cdc2 dephosphorylation is the immediate event that
accounts for the G2 block. More generally, CDT would inter-
fere, directly or indirectly, on a transduction pathway that
determines the state of phosphorylation of cdc2. In other
words, CDT may act directly on the phosphorylation/dephos-
phorylation machinery that regulates the activation of cdc2 at
FIG. 6. Expression of cyclin B1 in synchronized HeLa cells after exposure to
CDT or to the control preparation, determined by flow cytometry analysis. HeLa
cells were synchronized in G1/S by the DTB method. At release from the G1/S
block, they were exposed for 1 h to CDT-I or to the control preparation. They
were analyzed for cyclin B1 and DNA contents 4 h (S phase), 8 h (G2), or 11 h
(M) later. Cyclin B1 was stained by indirect immunofluorescence using FITC-
conjugated antibody as the secondary reagent and stained for DNA with PI.
Relative cyclin B1 content according to DNA content was determined by biva-
riate flow cytometry analysis. About 10,000 cells were analyzed per sample. The
average level of cyclin B1 content of the total population (arbitrary units), as
determined by CellQuest statistical software, appears in the upper right corner of
each analysis. Note that the cyclin B1 increase through S and G2 was not
significantly different in control cells and in CDT-treated cells up to 11 h (P 
0.05). After 11 h, cyclin B1 continued to increase in CDT-treated cells, while it
started to decline significantly in control cells (P  0.05), which progressed into
G1 phase.
FIG. 7. Expression of cyclin B1 in unsynchronized HeLa cells after exposure
to CDT or to the control preparation, determined by flow cytometry analysis.
HeLa cells were exposed for 1 h to CDT-I or to the control preparation. They
were analyzed for cyclin B1 and DNA contents 4 h, 16 h (G2), or 48 h later.
Cyclin B1 was stained by indirect immunofluorescence using FITC-conjugated
antibody as the secondary reagent and stained for DNA with PI. Relative cyclin
B1 content according to DNA content was determined by bivariate flow cytom-
etry analysis. About 10,000 cells were analyzed per sample. The average level of
cyclin B1 content of the total population (arbitrary units), as determined by
CellQuest statistical software, appears in the upper right corner of each analysis.
Note that in CDT-treated cells, which were blocked in G2 phase, cyclin B1
increased steadily up to at least 48 h after exposure.
mitosis or, alternatively, may impair cdc2 activation by induc-
ing the effect of a cyclin-dependent kinase inhibitor. In that
case, change in the phosphorylation status of cdc2 would be
only indirect and would reflect the cell cycle arrest prior to the
dephosphorylation event. Two immediately upstream molecu-
lar determinants of cdc2 phosphorylation are known at the
present time (5, 17). The first one is the cdc25 phosphatase,
which, upon activation, removes the inhibitory phosphate from
Thr-14 and Tyr-15 residues of cdc2. The second, antagonistic
to the first one, is the mammalian equivalent for yeast Wee1-
like tyrosine kinase, which phosphorylates cdc2 on Tyr-15 (9,
21). The possibility that one or the other of these effectors is
involved should be tested.
A further clue to the determinism of the G2 block caused by
CDT is provided by our demonstration that in contrast to cells
exposed in G1/S and S, most cells exposed in G2 and M are
blocked not at the current cycle but at the next one (Fig. 2).
This important observation means that passage through S
phase is required for the G2 block to be triggered. This would
imply that the toxin interferes with a transduction cascade that
is initiated in S phase, i.e., during DNA replication. Such a
cascade could be the so-called DNA damage checkpoint, which
is the mechanism that detects damaged DNA and generates a
signal that arrests cells in the G1 phase of the cell cycle, slows
down S phase, arrests cells in the G2 phase, and induces the
transcription of repair genes (6, 22). Two hypotheses can be
raised: either CDT is able to induce DNA damage, for exam-
ple, through acting on enzymes of the replication machinery, or
it interferes with early downstream components of the DNA
damage checkpoint system. In mammalian cells, only the G1
damage checkpoint is understood with some detail (6). It is
controlled by at least three genes, called ATM, p53, and p21.
p53 protein activates transcription of p21, a tight-binding in-
hibitor of the cyclin-dependent kinases that controls entry into
S phase. Much less is known regarding the determinism of the
G2 damage DNA checkpoint in mammalian cells (6, 22). In the
present study, HeLa cells accumulated most exclusively in G2
and insignificantly in G1 (except when cells were exposed in
G2), and the rate of their progression through S phase was not
affected, at least at the dose tested. These peculiarities are not
in contradiction with the potential involvement of the DNA
damage checkpoint, since expression of p53 and p21 is known
to be repressed in HeLa cells (10). In these conditions, activa-
tion of the DNA damage checkpoint in HeLa cells inevitably
results in a predominant G2 block due to lack of cdc2 activa-
tion, as already demonstrated in this cell line with such differ-
ent DNA-damaging agents as camptothecin, etoposide, nitro-
gen mustard (13–15), and ionizing radiations (1, 16). Another
consequence of our observation that a 1-h exposure to CDT
during G2-phase-induced blocking at the subsequent cell cycle
is that toxin activity is maintained through a complete cell
cycle, i.e., at least 20 h, in spite of its absence from the culture
medium. This conclusion is corroborated by the fact that the
overall sensitivity of cells exposed in G2 was not significantly
different from that of cells synchronized in G1/S or in S.
The inhibitory activity of CDT on cdc2 protein kinase acti-
vation has been demonstrated in the present study with the
three E. coli CDT types cloned so far (23, 24, 30). Moreover,
this property seems to apply as well to CDT from other bac-
terial species, since CDT from Campylobacter jejuni also ap-
pears to block cell cycle in G2 through inactivation of cdc2 (26).
Although the effect of CDT in cultured cells is novel for a
bacterial toxin, it bears striking similarities with that of a re-
cently discovered viral protein: the Vpr of human immunode-
ficiency virus type 1 (29). Vpr also causes a G2 block due to
inhibition of p34cdc2 in different cell lines, including HeLa cells
(29), through pathways that are similar to those used by DNA-
damaging agents. The relevance of the cell cycle inhibitory
effect of CDT in in vivo pathogenesis now remains to be ex-
plored. The fact that different variants of this toxin are found
in unrelated bacterial species such as S. dysenteriae (19, 20),
Campylobacter sp. (18, 25), and H. ducreyi (3) would indicate
that the in vivo biological function conferred by this factor
gives a highly selective advantage to its hosts. All of the patho-
gens mentioned above are pathogenic for epithelia, either the
intestinal epithelium (for E. coli, S. dysenteriae, and Campy-
lobacter sp.) or the vaginal epithelium (for H. ducreyi). The
pathogenic role of CDT in diarrheal diseases is substantiated
by the recent observation that CDT from S. dysenteriae is able
to induce tissue damage and fluid accumulation in the de-
scending colon of orally infected suckling mice (20). The rela-
tion between this in vivo effect and the inhibition of cell divi-
sion that we have investigated in the present study should now
be examined. One can speculate that the toxin is able to inhibit
the growth of actively dividing crypt cells, thus preventing the
rapid renewal of the epithelium and leading to the intestinal
lesions.
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immunoblot analysis) was purified by affinity on Sepharose-bound p13. Kinase
activity in precipitates was assessed by the level of [-32P]ATP incorporation by
histone H1 as measured by liquid scintillation counting (four determinations per
sample). Average numbers of counts per minute (minus background radioactiv-
ity) and standard errors are shown. The state of phosphorylation of cdc2 was
assessed by immunoblotting on a same membrane, first by probing with a mono-
clonal antibody against phosphotyrosine (P-Tyr) and then, after stripping of the
membrane, by reprobing with a polyclonal antibody against the carboxyl termi-
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inhibition was associated with hyperphosphorylation of the upper slow-migrating
form of cdc2.
We are also indebted to James Kaper and Carol Pickett for the gifts of
plasmids pDS7.96 and pCP2123, respectively.
This work was supported in part by grant 1335 from the European
Community Program FAIR and grant 9507783 from the Conseil Re´-
gional de la Re´gion Midi-Pyre´ne´es. S.Y.P. is a recipient of a scholar-
ship from the Ministe`re de l’Enseignement Supe´rieur et de la Recher-
che.
REFERENCES
1. Barth, H., I. Hoffmann, and V. Kinzel. 1996. Radiation with 1Gy prevents the
activation of the mitotic inducers mitosis-promoting factor (MPF) and
cdc25-C in HeLa cells. Cancer Res. 56:2268–2272.
2. Borgne, A., and L. Meijer. 1996. Sequential dephosphorylation of p34cdc2 on
Thr-14 and Tyr-15 at the prophase-metaphase transition. J. Biol. Chem.
271:27847–27854.
3. Cope, L. D., S. Lumbley, J. L. Latimer, J. Klesney-Tait, M. K. Stevens, L. S.
Johnson, M. Purven, R. S. Munson, Jr., T. Lagergard, J. D. Radolf, and E. J.
Hansen. 1997. A diffusible cytotoxin of Haemophilus ducreyi. Proc. Natl.
Acad. Sci. USA 94:4056–4061.
4. Draetta, G., and D. Beach. 1988. Activation of cdc2 protein kinase during
mitosis in human cells: cell cycle-dependent phosphorylation and subunit
rearrangement. Cell 54:17–26.
5. Dunphy, W. G. 1994. The decision to enter mitosis. Trends Cell Biol. 4:202–
207.
6. Elledge, S. J. 1996. Cell cycle checkpoints: preventing an identity crisis.
Science 274:1664–1672.
7. Fe´lix, M. A., P. R. Clarke, J. Coleman, F. Verde, and E. Karsenti. 1993.
Xenopus egg extracts as a system for studying mitosis, p. 253–283. In P.
Fantes, and R. Brooks (ed.), The cell cycle: a practical approach. IRL Press,
Oxford, England.
8. Gong, J., F. Traganos, and Z. Darzynkiewicz. 1995. Discrimination of G2
and mitotic cells by flow cytometry based on different expression of cyclins A
and B1. Exp. Cell Res. 220:226–231.
9. Heald, R., M. McLoughlin, and F. McKeon. 1993. Human Wee1 maintains
mitotic timing by protecting the nucleus from cytoplasmically activated cdc2
kinase. Cell 74:463–474.
10. Hwang, E. S., L. K. Naeger, and F. DiMaio. 1996. Activation of the endog-
enous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by
expression of the bovine papillomavirus E2 gene. Oncogene 12:795–803.
11. Jackson, P. K. 1996. Cell cycle: cull and destroy. Curr. Biol. 6:1209–1212.
12. Johnson, W. M., and H. Lior. 1988. A new heat-labile cytolethal distending
toxin produced by Campylobacter spp. Microb. Pathog. 4:115–126.
13. Lock, R. B., F. Galperina, R. C. Feldhoff, and L. J. Rhodes. 1994. Concen-
tration-dependent differences in the mechanisms by which caffeine potenti-
ates etoposide cytotoxicity in HeLa cells. Cancer Res. 54:4933–4939.
14. Lock, R. B., and P. K. Killing. 1993. Responses of HeLa and Chinese
hamster ovary cdc2/cyclin-B kinase in relation to cell cycle perturbations
induced by etoposide. Int. J. Oncol. 3:33–42.
15. Maity, A., A. Hwang, A. Janss, P. Philips, W. J. McKenna, and W. G.
Muschel. 1996. Delayed cyclin B1 expression during the G2 arrest following
DNA damage. Oncogene 13:1647–1657.
16. Metting, N. F., and J. B. Little. 1995. Transient failure to dephosphorylate
cdc2-cyclin B1 complex accompanies radiation-induced G2 phase arrest in
HeLa cells. Radiat. Res. 143:286–292.
17. Norbury, C., and P. Nurse. 1992. Animal cell cycles and their control. Annu.
Rev. Biochem. 61:441–470.
18. Ohya, T., K. Tominaga, and K. Nakazawa. 1993. Production of cytolethal
distending toxin (CLDT) by Campylobacter fetus subsp. fetus isolated from
calves. J. Vet. Med. Sci. 55:507–509.
19. Okuda, J., H. Kurazono, and Y. Takeda. 1995. Distribution of the cytolethal
distending toxin A gene (cdtA) among species of Shigella and Vibrio, and
cloning and sequencing of the cdt gene from Shigella dysenteriae. Microb.
Pathog. 18:167–172.
20. Okuda, J., M. Fukumoto, Y. Takeda, and M. Nishibuchi. 1997. Examination
of diarrheagenicity of cytolethal distending toxin: suckling mouse response to
the products of the cdtABC genes of Shigella dysenteriae. Infect. Immun.
65:428–433.
21. Parker, L. L., P. J. Sylvestre, M. J. Byrnes III, F. Liu, and H. Piwnica-Worns.
1995. Identification of a 95-kDa WEE1-like tyrosine kinase in Hela cells.
Proc. Natl. Acad. Sci. USA 92:9638–9642.
22. Paulovitch, A. G., D. P. Toczyski, and L. H. Hartwell. 1997. When check-
points fail. Cell 88:315–321.
23. Pe´re`s, S. Y., O. Marche`s, F. Daigle, J. P. Nougayre`de, F. He´rault, C. Tasca,
J. De Rycke, and E. Oswald. 1997. A new cytolethal distending toxin (CDT)
from Escherichia coli producing CNF2 blocks Hela cell division in G2/M
phase. Mol. Microbiol. 24:1095–1107.
24. Pickett, C. L., D. L. Cottle, E. C. Pesci, and G. Bikah. 1994. Cloning,
sequencing, and expression of the Escherichia coli cytolethal distending toxin
genes. Infect. Immun. 62:1046–1051.
25. Pickett, C. L., E. C. Pesci, D. L. Cottle, G. Russell, A. N. Erdem, and H.
Zeytin. 1996. Prevalence of cytolethal distending toxin production in Campy-
lobacter jejuni and relatedness of Campylobacter sp. cdt genes. Infect. Immun.
64:2070–2078.
26. Pickett, C. L. 1997. Cytolethal distending toxin causes a G2 phase cell cycle
block, abstr. B-259, p. 73. In Abstracts of the 97th General Meeting of the
American Society for Microbiology 1997. American Society for Microbiol-
ogy, Washington, D.C.
27. Pines, J., and T. Hunter. 1991. Human cyclins A and B1 are differentially
located in the cell and undergo cell-cycle-dependent nuclear transport. J.
Cell Biol. 115:1–17.
28. Planelles, V., J. B. M. Jowett, Q. X. Li, Y. Xie, B. Hahn, and I. S. Y. Chen.
1996. Vpr-induced cell cycle arrest is conserved among primate lentiviruses.
J. Virol. 70:2516–2524.
29. Poon, B., J. B. M. Jowett, S. A. Stewart, R. W. Armstrong, G. M. Rishton, and
I. S. Y. Chen. 1997. Human immunodeficiency virus type 1 vpr gene induces
phenotypic effects similar to those of the DNA alkylating agent, nitrogen
mustard. J. Virol. 71:3961–3971.
30. Scott, D. A., and J. B. Kaper. 1994. Cloning and sequencing of the genes
encoding Escherichia coli cytolethal distending toxin. Infect. Immun. 62:244–
251.
31. Stein, G., and J. L. Stein. 1990. Cell synchronization, p. 133–137. In R. I.
Frishney (ed.), Cell growth and division, a practical approach. IRL Press,
Oxford, England.
32. Tsao, Y., P. D’Arpa, and L. F. Liu. 1992. The involvement of active DNA
synthesis in camptothecin-induced G2 arrest: altered regulation of cdc2/
cyclin B. Cancer Res. 52:1823–1829.
